P
rogressive fibrosis is the most important predictor for liver-related outcomes among patients with nonalcoholic fatty liver disease (NAFLD). Signaling by extracellular nucleotides, such as extracellular adenosine triphosphate and adenosine, are ubiquitous pathways involved in immune regulation and tissue regeneration. 1 Ectonucleoside triphosphate diphosphohydrolases rapidly phosphohydrolyze extracellular adenosine triphosphate and adenosine diphosphate (ADP) to adenosine monophosphate (AMP), which then is converted to adenosine by 5'-nucleotidase. Adenosine deaminase (ADA) converts adenosine or deoxyadenosine to inosine and derivatives. Two ADA enzymes exist in human beings. ADA1 is ubiquitous both as an intracellular enzyme and an ecto-enzyme on the surface of selected lymphocytes and endothelial cells through CD26. In comparison, ADA2 is a largely secreted protein produced by activated monocytes and dendritic cells. 2 Recent studies have shown that loss-of-function mutations in ADA2 render a proinflammatory phenotype in macrophages, manifesting clinically in vasculitis and early stroke.
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Methods
We measured the rate of 3 tandem enzyme activities in extracellular ADP metabolism in the serum of 100 biopsy-proven NAFLD patients and studied their crosssectional association to liver fibrosis ( Figure 1A ). These patients were selected from a previously described prospective NAFLD registry to approximate an equal distribution of fibrosis stages. 5 Blood samples were collected at the index visit. Liver biopsies performed within 3 months of enrollment were reviewed by a hepatobiliary pathologist to ensure the consistency of pathologic interpretation. Adenosine diphosphatase and 5'-nucleotidase activities were measured using 14 C-ADP and 14 C-AMP as substrate as described previously. 6 Total ADA and ADA2 activities were measured using adenosine deaminase assay kits (Diazyme, Poway, CA). Immunohistochemistry was performed on formalin-fixed, paraffin-embedded biopsy specimens using a rabbit anti-ADA2 polyclonoal antibody (SigmaAldrich, St. Louis, MO). Laboratory researchers were blinded to the histopathologic diagnosis. All statistical analyses were performed using Stata 13.1 (StataCorp, College Station, TX).
Results
Among 100 patients in the study, 41 were female, 89 were diagnosed with nonalcoholic steatohepatitis (NASH), 57 had stages 2 to 4 fibrosis, and 12 had cirrhosis. Among the 3 enzymatic steps, the rate of conversion from adenosine to inosine via ADA was significantly higher among patients with stages 2 to 4 fibrosis compared with patients with stages 0 to 1 fibrosis (18.7 AE 6.9 vs 14.8 AE 5.0 U/L, respectively), whereas the rates of conversion from ADP to AMP and AMP to adenosine were not significantly different. Between the 2 ADA isoforms, ADA2 accounted for this difference in the deaminase activity ( Figure 1B) . In a sensitivity analysis excluding stage 4 fibrosis, ADA2 activity remained strongly associated with fibrosis stage (P ¼ .001). There was no ADA2 activity difference between patients with and without NASH, although the number of patients with simple steatosis was small (n ¼ 11). Immunohistochemistry of the liver tissue showed intracellular ADA2 staining in mononuclear cells in the portal area, fibrotic bands, and sinusoidal cells, consistent with the distribution of macrophages and Kupffer cells ( Figure 1C) .
To evaluate the diagnostic value of serum ADA2 activity, receiver operating curve (ROC) analysis was performed. Compared with conventional indices of liver fibrosis, the performance of serum ADA2 activity was similar or superior than Fibrosis-4, NAFLD Fibrosis Score, and AST to Platelet Ratio Index in predicting cirrhosis, stage 3þ, and stage 2þ liver fibrosis with an area under the receiver operating curve (AUROC) of 0.94, 0.82, and 0.84, respectively ( Figure 1D ).
Discussion
This study showed a positive cross-sectional association between the circulating activity of ADA2, a macrophage-derived deaminase, and liver fibrosis in NAFLD. The emerging association between ADA2 deficiency and vasculitis suggests a potential mechanistic link underscoring this association, in which ADA2 modulates macrophage phenotype and impacts fibrogenesis.
ADA2 expression was observed in both infiltrative and resident macrophages in the liver. Defects in ADA2 have been linked to impaired macrophage M2 polarization in vitro, a phenotype that has been thought to be largely anti-inflammatory, but also can lead to fibrosis during repair and regeneration. 4, 7 A positive association between serum ADA2 activity and liver fibrosis is potentially driven by a shift of macrophage polarization toward an anti-inflammatory, but profibrotic, M2 phenotype. The molecular mechanism underlying ADA2-driven M2 polarization and its impact on liver fibrosis remains to be delineated.
Our study showed that serum ADA2 activity is of diagnostic value in predicting liver fibrosis. Its performance was noninferior to validated noninvasive fibrosis indices such as Fibrosis-4, NAFLD Fibrosis Score, and AST to Platelet Ratio Index in our cohort. It will be interesting to know whether ADA2 activity correlates with soluble CD163, a biomarker for liver fibrosis in various etiologies that also is related to macrophage activity. 8 Further study is needed to clarify the molecular mechanism of ADA2 in regulating fibrosis and to validate its diagnostic value in NAFLD as well as other forms of chronic liver disease, and in larger cohorts that can reflect the disease spectrum in the community. 
